WO2015134603A3 - Procédés de traitement du cancer - Google Patents

Procédés de traitement du cancer Download PDF

Info

Publication number
WO2015134603A3
WO2015134603A3 PCT/US2015/018724 US2015018724W WO2015134603A3 WO 2015134603 A3 WO2015134603 A3 WO 2015134603A3 US 2015018724 W US2015018724 W US 2015018724W WO 2015134603 A3 WO2015134603 A3 WO 2015134603A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating cancer
subject
mll
ptd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/018724
Other languages
English (en)
Other versions
WO2015134603A2 (fr
Inventor
Roy Macfarlane Pollock
Scott Richard Daigle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epizyme Inc
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of WO2015134603A2 publication Critical patent/WO2015134603A2/fr
Publication of WO2015134603A3 publication Critical patent/WO2015134603A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés qui consistent à diagnostiquer si un sujet présente un MLL-PTD et, si le sujet présente un MLL-PTD, à lui administrer une quantité thérapeutiquement efficace d'un inhibiteur de DOT1L.
PCT/US2015/018724 2014-03-05 2015-03-04 Procédés de traitement du cancer Ceased WO2015134603A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461948499P 2014-03-05 2014-03-05
US61/948,499 2014-03-05
US201461951622P 2014-03-12 2014-03-12
US61/951,622 2014-03-12
US201461990477P 2014-05-08 2014-05-08
US61/990,477 2014-05-08

Publications (2)

Publication Number Publication Date
WO2015134603A2 WO2015134603A2 (fr) 2015-09-11
WO2015134603A3 true WO2015134603A3 (fr) 2015-11-19

Family

ID=54055986

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/018724 Ceased WO2015134603A2 (fr) 2014-03-05 2015-03-04 Procédés de traitement du cancer

Country Status (1)

Country Link
WO (1) WO2015134603A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
WO2016090271A1 (fr) * 2014-12-05 2016-06-09 Epizyme, Inc. Traitement de la leucémie par administration de l'inhibiteur de dot1l pinometostat
GB201519573D0 (en) * 2015-11-05 2015-12-23 King S College London Combination

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096255A1 (en) * 1997-02-19 2003-05-22 Felix Carolyn A. Methods and kits for analysis of chromosomal rearrangements associated with cancer
US20090269751A1 (en) * 2003-06-13 2009-10-29 University Of North Carolina At Chapel Hill Dot1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
US20100190656A1 (en) * 2008-08-08 2010-07-29 Integrated Diagnostics, Inc. Breast Cancer Specific Markers and Methods of Use
US20120272346A1 (en) * 2009-03-27 2012-10-25 Bruce Stillman Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096255A1 (en) * 1997-02-19 2003-05-22 Felix Carolyn A. Methods and kits for analysis of chromosomal rearrangements associated with cancer
US20090269751A1 (en) * 2003-06-13 2009-10-29 University Of North Carolina At Chapel Hill Dot1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
US20100190656A1 (en) * 2008-08-08 2010-07-29 Integrated Diagnostics, Inc. Breast Cancer Specific Markers and Methods of Use
US20120272346A1 (en) * 2009-03-27 2012-10-25 Bruce Stillman Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAIGLE, SR ET AL.: "Potent Inhibition Of DOT1L As Treatment Of MLL-Fusion Leukemia.", BLOOD., vol. 122, no. 6, 8 August 2013 (2013-08-08), pages 1017 - 1025, XP055237436 *

Also Published As

Publication number Publication date
WO2015134603A2 (fr) 2015-09-11

Similar Documents

Publication Publication Date Title
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
WO2016044189A8 (fr) Méthodes de traitement du cancer faisant appel à un antagoniste se liant à l'axe pd-1 et à des antagonistes se liant à l'il-17
WO2015185875A9 (fr) Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs
MX2017001154A (es) Metodos y combinaciones terapeuticas para tratar tumores.
WO2015073587A3 (fr) Complexes membrane synthétique- récepteur
EP3256218A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
PT2976360T (pt) Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro
EP3307240A4 (fr) Polythérapie pour le traitement du cancer
EP3182989A4 (fr) Méthodes et compositions destinées à prévenir et à traiter une maladie
ZA201706402B (en) C.novyi for the treatment of solid tumors in humans
WO2017044807A3 (fr) Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
WO2015179835A3 (fr) Biomarqueurs mit et leurs méthodes d'utilisation
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
MX379622B (es) Compuestos espirociclicos
EP3548007A4 (fr) Méthodes de traitement du cancer
WO2017103280A9 (fr) Traitement intravésical du cancer de la vessie
EP3188800A4 (fr) Compositions et méthodes de traitement de troubles fibrosants et du cancer
WO2015138761A3 (fr) Méthodes pour traiter une lésion du nerf périphérique
WO2015134603A3 (fr) Procédés de traitement du cancer
PH12016502311A1 (en) Omega-3 analogues
EP2994156A4 (fr) Composés, compositions et procédés permettant le traitement des maladies par inhibition de l'activité de tgf-
WO2016040313A3 (fr) Méthodes de traitement du cancer
WO2019028012A3 (fr) Procédés d'utilisation de pembrolizumab et de trébananib
EP3181562A4 (fr) Composés dérivés de phénylaminopyrimidine, procédé d'obtention, utilisation desdits composés dans le traitement du cancer et méthodes de traitement
WO2015113041A3 (fr) Compositions et procédés de traitement de maladies autoimmunes et inflammatoires

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15758057

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15758057

Country of ref document: EP

Kind code of ref document: A2